In Vitro Evaluation of Dendrimer-Polymer Hybrid Nanoparticles on Their Controlled Cellular Targeting Kinetics

被引:46
作者
Sunoqrot, Suhair [1 ]
Liu, Ying [2 ]
Kim, Dong-Hwan [4 ]
Hong, Seungpyo [1 ,3 ]
机构
[1] Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA
[2] Univ Illinois, Dept Chem Engn, Chicago, IL 60612 USA
[3] Univ Illinois, Dept Bioengn, Chicago, IL 60612 USA
[4] Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore 637457, Singapore
关键词
dendrimers; folk acid; hybrid nanoparticles; multiscale; targeting; ANTICANCER DRUG-DELIVERY; TUMOR-BEARING MICE; POLY(AMIDOAMINE) DENDRIMERS; MULTICELLULAR SPHEROIDS; MONOLAYER-CULTURES; CANCER-THERAPY; FOLATE; SIZE; NANOCARRIERS; PENETRATION;
D O I
10.1021/mp300560n
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Although polymeric nanoparticles (NPs) and dendrimers represent some of the most promising cancer-targeting nanocarriers, each of them has drawbacks such as limited tissue diffusivity/tumor penetration and rapid in vivo elimination, respectively. To address these issues, we have designed a multiscale hybrid NP system (nanohybrid) that combines folate (FA) targeted poly(amidoamine) dendrimers and poly(ethylene glycol)-b-poly(D,L-lactide) NPs. The nano-hybrids (similar to 100 nm NPs encapsulating similar to 5 nm targeted dendrimers) were extensively characterized through a series of in vitro experiments that validate the design rationale of the system, in an aim to simulate their in vivo behaviors. Cellular uptake studies using FA receptor. (FR)-overexpressing KB cells (KB FR+) revealed that the nanohybrids maintained high FR selectivity resembling the selectivity of free dendrimers, while displaying temporally controlled cellular interactions due to the presence of the polymeric NP shells. The cellular interactions of the nanohybrids were clathrin-dependent (characteristic of polymer NPs) at early incubation time points (4 h), which were partially converted to caveolae-mediated internalization (characteristic of FA targeted dendrimers) at longer incubation hours (24 h). Simulated penetration assays using multicellular tumor spheroids of KB FR+ cells also revealed that the targeted dendrimers penetrated deep into the spheroids upon their release from the nanohybrids, whereas the NP shell did not Additionally, methotrexate-containing systems showed the selective, controlled cytotoxicity kinetics of the nanohybrids. These results all demonstrate that our nanohybrids successfully integrate the unique characteristics of dendrimers (effective targeting and penetration) and polymeric NPs (controlled release and suitable size for long circulation) in a kinetically controlled manner.
引用
收藏
页码:2157 / 2166
页数:10
相关论文
共 38 条
[1]
Dendron-mediated self-assembly of highly PEGylated block copolymers: a modular nanocarrier platform [J].
Bae, Jin Woo ;
Pearson, Ryan M. ;
Patra, Niladri ;
Sunoqrot, Suhair ;
Vukovic, Lela ;
Kral, Petr ;
Hong, Seungpyo .
CHEMICAL COMMUNICATIONS, 2011, 47 (37) :10302-10304
[2]
Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
[3]
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery [J].
Danhier, Fabienne ;
Feron, Olivier ;
Preat, Veronique .
JOURNAL OF CONTROLLED RELEASE, 2010, 148 (02) :135-146
[4]
Davies CD, 1997, ANTICANCER RES, V17, P4317
[5]
Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: Enhanced efficacy and intratumoral transport capability [J].
Dhanikula, Renu Singh ;
Argaw, Anteneh ;
Bouchard, Jean-Francois ;
Hildgen, Patrice .
MOLECULAR PHARMACEUTICS, 2008, 5 (01) :105-116
[6]
Polymer conjugates as anticancer nanomedicines [J].
Duncan, Ruth .
NATURE REVIEWS CANCER, 2006, 6 (09) :688-701
[7]
Eavarone DA, 2000, J BIOMED MATER RES, V51, P10, DOI 10.1002/(SICI)1097-4636(200007)51:1<10::AID-JBM2>3.0.CO
[8]
2-R
[9]
Spheroid-based drug screen: considerations and practical approach [J].
Friedrich, Juergen ;
Seidel, Claudia ;
Ebner, Reinhard ;
Kunz-Schughart, Leoni A. .
NATURE PROTOCOLS, 2009, 4 (03) :309-324
[10]
Gabizon A, 2003, CLIN CANCER RES, V9, P6551